Filtered By:
Source: Heart Rhythm
Condition: Thrombosis
This page shows you your search results in order of date.
Order by Relevance | Date
Total 34 results found since Jan 2013.
Po-03-175 cost-effectiveness of transesophageal echocardiogram prior to atrial fibrillation ablation.
With universal adoption of uninterrupted anticoagulation (AC) it is suggested that transesophageal echo (TEE) screening for LA (left atrial) thrombus prior to AF ablation procedure could be omitted. Observational studies suggest that post-procedure stroke might not be completely prevented by TEE. Accumulating data on safety of AF ablation on uninterrupted AC together with a risk of TEE complications raise the question of indications for TEE in all AF ablation patients.
Source: Heart Rhythm - May 1, 2023 Category: Cardiology Authors: Olga Reynbakh, Clyde B. Schechter, Mario J. Garcia, Leandro Slipczuk Bustamante, Hardikkumar Patel, Xiaodong Zhang, Fengwei Zou, Luigi Di Biase Source Type: research
Po-01-002 association of novel combined genetic polymorphisms with risk of thromboembolism in patients with atrial fibrillation
AF patients remain on oral anticoagulation (OAC) or left atrial appendage (LAA) closure is performed for thromboprophylaxis. However, clots on the closure device as well as stroke/transient ischemic attack (TIA) are observed to occur in some patients despite of being on blood thinners or after being off-OAC for a very brief period.
Source: Heart Rhythm - May 1, 2023 Category: Cardiology Authors: Sanghamitra Mohanty, Amitabh C. Pandey, Bryan MacDonald, Angel Quintero Mayedo, Carola Gianni, Prem Geeta Torlapati, Vincenzo Mirco La Fazia, Domenico G. Della Rocca, Mohamad Bassiouny, G. Joseph Gallinghouse, John D. Burkhardt, Rodney P. Horton, Amin Al- Source Type: research
Contemporary Trends in Utilization and Outcomes of Percutaneous Left Atrial Appendage Occlusion in the United States from 2016 to 2019
Atrial fibrillation is a major cause of stroke and thromboembolism and oral anticoagulation is the mainstay of prevention. In patients who are poor candidates for long-term anticoagulation, percutaneous left atrial appendage occlusion (pLAAO) emerged as an alternative stroke prevention strategy and was approved by the US FDA in 2015. We aimed to examine trends in procedural volume, resource utilization, and clinical outcomes of pLAAO from a nationally representative cohort.
Source: Heart Rhythm - October 14, 2022 Category: Cardiology Authors: Mohak Gupta, Abdul Mannan Khan Minhas, Sachin S. Goel, Sourbha S. Dani, Mahboob Alam, Salik Nazir, Safi U. Khan, Wilbert Aronow, Vardhmaan Jain Source Type: research
Anticoagulation Management and Risk of Thromboembolism in Healthy Youth with Atrial Fibrillation: Data from a Multi-Institutional PACES Collaborative Registry
Stroke is a well-defined complication of atrial fibrillation (AF) in adults. Risks and benefits of anticoagulation management in this patient population are extensively studied resulting in well-defined clinical practice guidelines.1 On the other hand, there is limited data in healthy children and young adults.
Source: Heart Rhythm - August 3, 2022 Category: Cardiology Authors: Iqbal El Assaad, Benjamin H. Hammond, Peter F. Aziz, Participating Members of the Pediatric and Congenital Electrophysiology Society, Christopher Janson, Elizabeth Dr Sherwin, Elizabeth A. Stephenson, Christopher L. Johnsrude, Mary Niu, Ira Shetty, David Source Type: research
Po-620-04 intra-operative findings with massive device-related thrombus after percutaneous left atrial appendage closure: mechanistic insights
Left atrial appendage closure (LAAC) devices are an alternative to antithrombotic therapy for stroke prevention in high-risk patients with atrial fibrillation who are not candidates for systemic anticoagulation. However, device related thrombus (DRT) has an observed incidence of ∼4% after LAAC. The mechanism of massive thrombus formation remains incompletely understood.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Kashif Malik, Rong Bai, Damir Vukomanovic, Alicia Taase, Eleanor Kitchell, Rinku Skaria, Roderick Tung, Kenith Fang, Michael S. Zawaneh Source Type: research
Ce-543-04 inter-atrial block identifies patients with low cha2ds2-vasc score but high stroke risk
Beyond current methods of risk stratification, clinical studies employing machine learning methodology have demonstrated that the 12-lead ECG harbors additional prognostic information for various cardiovascular outcomes. Interatrial block (IAB) manifests as P wave duration>120 msec and is associated with thromboembolism, atrial arrhythmias, and mortality.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Joshua Lampert, Shreyas Havaldar, David Power, Marc A. Miller, Abhishek Maan, Kartikeya Menon, Emmanuel Ekanem, Jonathan Gandhi, Daniel N. Pugliese, Daniel Ross Musikantow, Mohit K. Turagam, Valentin Fuster, Srinivas R. Dukkipati, Benjamin Glicksberg, Viv Source Type: research
Po-674-04 anticoagulation management and risk of thromboembolism in healthy youth with atrial fibrillation: data from a multi-institutional paces collaborative registry
Stroke is a well-defined complication of atrial fibrillation (AF) in adults. However, the risk of thromboembolism and need for anticoagulation therapy in children and young adults with AF are unknown.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Iqbal El Assaad, Benjamin Hammond, Christopher M. Janson, Elizabeth D. Sherwin, Elizabeth A. Stephenson, Christopher L. Johnsrude, Mary C. Niu, Ira Shetty, David K. Lawrence, Anthony C. McCanta, Seshadri Balaji, Shubhayan Sanatani, Frank A. Fish, Gregory Source Type: research
Po-670-07 optimising antithrombotic agents in patients undergoing left atrial appendage occlusion
Anticoagulants and/or antiplatelet agents are used in the perioperative period for left atrial appendage occluder (LAAO) implantation to reduce the risk of stroke related to atrial fibrillation (AF) or thrombus from the device. However, the indication for LAAO is often a bleeding condition that may be exacerbated by these drugs.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Balrik Kailey, Michael Koa-Wing, Norman A. Qureshi, Syed M. Sohaib, Christine Shi, Pritpal Padam, James Howard, Prapa Kanagaratnam Source Type: research
Po-670-06 efficacy and safety of left atrial appendage occlusion during cardiac surgery to prevent stroke: a systematic review and meta-analysis
Stroke remains one of the significant causes of morbidity and mortality after cardiac surgery. One stroke occurrence is postoperative atrial fibrillation (pAF), with an incidence ranging between 20% and 40%. PAF predisposes to the formation of atrial thrombus. Most thrombus formations observed in the left atrial appendage (LAA) have triggered significant interest as a potential therapeutic target. Current guidelines recommend the administration of direct oral anticoagulants (DOACs) as the preferred therapy to prevent stroke in patients with atrial fibrillation with a CHA2DS2-VASc of ≥ 2.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Reynald Evan Tugade, Billy Joseph David, Clara Sy Tolentino Source Type: research
B-po02-154 figure of eight sutures in fully anticoagulated patients after left atrial appendage occlusion may obviate need for anticoagulation reversal
There are limited data regarding vascular access site management after left atrial appendage occlusion (LAAO). Intravenous protamine is widely used to reverse anticoagulation but has potential for serious adverse reactions including anaphylaxis, thrombosis, and stroke.
Source: Heart Rhythm - July 28, 2021 Category: Cardiology Authors: Saket Sanghai, Uday Sandhu, Christopher Verdick, Harsh Golwala, Charles A. Henrikson Source Type: research
B-ab17-01 left atrial closure device thrombosis is associated with systemic embolization
Cardioembolic stroke and systemic embolism (CS/SE) represents the most severe complication of atrial fibrillation. Approximately 92% of intracardiac thrombosis originates from the left atrial appendage (LAA) and, although its mechanical occlusion is a proved method to prevent cardioembolism, thrombosis of all types of LAA occlusion devices and their associations with CS/SE were observed.
Source: Heart Rhythm - July 28, 2021 Category: Cardiology Authors: Pavel Hala, Veronika Lekesova, Tomas Mraz, Milena Prokopova, Jan Petru, Lucie Sediva, Marek Janotka, Kristina Molnarova, Petr Neuzil, Vivek Y. Reddy Source Type: research
B-po05-005 multi-physics, patient-specific computational modeling of la electrophysiology, biomechanics and hemodynamics reveals mechanistic connections between fibrotic remodeling and thrombosis risk
Fibrosis is a relevant clinical factor involved in AF and stroke, but it remains impossible to predict how a given fibrosis pattern disrupts left atrial (LA) electrophysiology (EP), wall motion, and blood flow in a biophysically integrative manner.
Source: Heart Rhythm - July 28, 2021 Category: Cardiology Authors: Alejandro Gonzalo, Christoph M. Augustin, Manuel Garc ía-Villalba, Pablo Martínez-Legazpi, Oscar Flores, Javier Bermejo, Elliot McVeigh, Andrew M. Kahn, Gernot Plank, Nazem Akoum, Juan C. del Álamo, Patrick Boyle Source Type: research
B-po05-199 differences in stroke or systemic thromboembolism readmissions after hospitalization for atrial fibrillation or atrial flutter
Although atrial fibrillation (AF) and atrial flutter (AFL) are different arrhythmias, they are assumed to confer the same risk of stroke and systemic thromboembolism (STE) despite a lack of available evidence.
Source: Heart Rhythm - July 28, 2021 Category: Cardiology Authors: Harshith Thyagaturu, Alexander Bolton, Sittinun Thangjui, Dinesh Voruganti, Hakan Paydak Source Type: research
B-po04-143 safety and feasibility of reactive atrial-based anti-tachycardia pacing algorithm in cardiovascular implantable electronic devices to suppress atrial fibrillation in patients with left atrial appendage closure device
Reactive atrial-based anti-tachycardia pacing (rATP) in CIED (cardiovascular implantable electronic devices) are effective in AF suppression. Uninterrupted systemic anticoagulation is mandated when these algorithms are activated to avoid stroke and systemic thromboembolism. However, the use of rATP algorithm in patients with left atrial appendage (LAA) closure device without ongoing anticoagulation has not been studied.
Source: Heart Rhythm - July 28, 2021 Category: Cardiology Authors: Rayan El-Zein, Jordan Luli, Ishmail Saccoh, Cody Carter, Mitchell Stelzer, Emily M. Gates, Zeryab Khan, Ankur N. Shah, James M. Kleman, Sreedhar R. Billakanty, Anish K. Amin, Nagesh Chopra Source Type: research
B-po04-141 left atrial appendage occlusion versus oral anticoagulation as primary strategies to prevent laa thrombus and stroke following left atrial appendage electrical isolation: apropensity score-matched analysis
Left atrial appendage electrical isolation (LAAEI) has been shown to be an effective strategy in catheter ablation (CA) for atrial fibrillation (AF). However, its widespread adaptability is limited because patients must be on lifelong oral anticoagulation (OAC) irrespective of their CHA2DS2VASc score and due to some concerns about increased risk of thromboembolic events (TE) despite OAC.
Source: Heart Rhythm - July 28, 2021 Category: Cardiology Authors: Jorge Romero, Dhanunjaya R. Lakkireddy, Isabella Alviz, Juan C. Diaz, David F. Briceno, Abhishek Jaiswal, Alejandro Velasco, Carolina R. Valencia, Dalvert Polanco, Daniel Rodriguez, Mohamed Gabr, Joseph Karpenos, Chintan G. Trivedi, Sanghamitra Mohanty, Source Type: research
